Collegium

Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

Retrieved on: 
Wednesday, July 21, 2021
Finance, Financial markets, Corporate finance, Earnings call, Stock market, Teleconferencing, NASDAQ, Collegium, Money

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time.

Key Points: 
  • STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time.
  • The Company will discuss its financial results and provide a corporate update.
  • To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the Collegium Pharmaceutical Q2 2021 Earnings Call.
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.

Collegium to Participate in Upcoming Investor Conference

Retrieved on: 
Thursday, May 20, 2021
Collegium, Government reform of Peter the Great

b'STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference:\nThe presentation will be webcast live and may be accessed from the Investor section of the Company\xe2\x80\x99s website: https://ir.collegiumpharma.com .

Key Points: 
  • b'STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference:\nThe presentation will be webcast live and may be accessed from the Investor section of the Company\xe2\x80\x99s website: https://ir.collegiumpharma.com .
  • A replay of the webcast will be available on the Company\xe2\x80\x99s website for approximately 30 days after the event.\nCollegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.
  • Collegium\xe2\x80\x99s headquarters are located in Stoughton, Massachusetts.
  • For more information, please visit the company\xe2\x80\x99s website at www.collegiumpharma.com .\n'

Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, February 11, 2021
Corporate finance, Earnings call, Stock market, Teleconferencing, Collegium, Conference call, Articles, Economy

The Company will discuss its financial results and provide a corporate update.

Key Points: 
  • The Company will discuss its financial results and provide a corporate update.
  • To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the Collegium Pharmaceutical Q4 2020 Earnings Call.
  • An audio webcast will be accessible from the Investors section of the Companys website: www.collegiumpharma.com .
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.

Collegium Provides 2021 Financial Guidance

Retrieved on: 
Wednesday, January 6, 2021
Fundamental analysis, Collegium, Government reform of Peter the Great, Tapentadol, Earnings before interest, taxes, depreciation and amortization, Economy

STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance.

Key Points: 
  • STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance.
  • Collegium achieved a financially transformative year in 2020, driven by Xtampza ER growth and the acquisition of the Nucynta franchise.
  • Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure, said Paul Brannelly, Executive Vice President and Chief Financial Officer of Collegium.
  • Collegium is not providing forward-looking guidance for its full-year 2021 U.S. GAAP net income (loss) or a quantitative reconciliation of forward-looking adjusted EBITDA.

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, October 22, 2020
Finance, Financial markets, Corporate finance, Earnings call, Stock market, Teleconferencing, Collegium, Conference call, NASDAQ, Money

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time.

Key Points: 
  • STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time.
  • The Company will discuss its financial results and provide a corporate update.
  • To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the Collegium Q3 Earnings Call.
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.

Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation

Retrieved on: 
Wednesday, September 30, 2020
Articles, Science and technology in Israel, Life sciences, Teva Pharmaceuticals, Collegium, Patent, Industries, Teva

As a result of the settlement, Teva has agreed to a consent judgment confirming that its proposed generic products infringe Collegiums asserted patents and that those patents are valid and enforceable with respect to Tevas proposed generic products.

Key Points: 
  • As a result of the settlement, Teva has agreed to a consent judgment confirming that its proposed generic products infringe Collegiums asserted patents and that those patents are valid and enforceable with respect to Tevas proposed generic products.
  • We are pleased with the outcome of the ANDA settlement with Teva because it highlights the value of that innovation in the context of the Xtampza ER franchise, said Shirley Kuhlmann, Executive Vice President and General Counsel of Collegium.
  • The resolution of this litigation reinforces the strength of Collegiums intellectual property portfolio, which includes 19 Orange Book-listed patents covering Xtampza ER with expiries through 2036, and our commitment to innovation in responsible pain management.
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.

Collegium Appoints Rita Balice-Gordon to its Board of Directors

Retrieved on: 
Friday, September 25, 2020
Articles, Collegium, Government reform of Peter the Great, Pain management, Board of directors

STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24, 2020.

Key Points: 
  • STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24, 2020.
  • Collegium is honored to welcome Rita to our Board of Directors, said Mike Heffernan, Founder and Chairman of the Board of Collegium.
  • We are confident that she will make meaningful contributions to our Board of Directors and that Collegium will benefit from her insights as we continue our commitment to leadership in responsible pain management.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

Retrieved on: 
Tuesday, July 21, 2020
Finance, Financial markets, Corporate finance, Earnings call, Stock market, Teleconferencing, Collegium, Conference call, NASDAQ, Money

STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time.

Key Points: 
  • STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time.
  • The Company will discuss its financial results and provide a corporate update.
  • To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the Collegium Q2 Earnings Call.
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.

Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work

Retrieved on: 
Wednesday, June 17, 2020
Collegium, Pharmaceutical industry

STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journals 2020 Best Places to Work.

Key Points: 
  • STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journals 2020 Best Places to Work.
  • We are honored to be recognized by the Boston Business Journal, and importantly, by our employees, as one of Bostons best places to work, said Joe Ciaffoni, President and Chief Executive Officer of Collegium.
  • The Boston Business Journals Best Places to Work program recognizes companies that have built extraordinary work environments for their people.
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.

Collegium to Participate in Upcoming Investor Conference

Retrieved on: 
Tuesday, April 7, 2020
Collegium

STOUGHTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April:

Key Points: 
  • STOUGHTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April:
    The 19th Annual Needham Healthcare Conference on Tuesday, April 14th.
  • Management will participate in a virtual fireside chat at 1:30 p.m.
  • The presentation will be webcast live and may be accessed from the Investor section of the Companys website: https://ir.collegiumpharma.com .
  • Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.